Product logins

Find logins to all Clarivate products below.


Blog: Commercialization

Here you will find relevant articles and insight into all Clarivate related products and news.

Tracking the mid-year momentum of the 2026 Drugs to Watch Tracking the mid-year momentum of the 2026 Drugs to Watch
Blog July 8, 2026
Tracking the mid-year momentum of the 2026 Drugs to Watch
Biopharma Biotech Clinical trials
Navigating global risk in the pharmaceutical supply chain Navigating global risk in the pharmaceutical supply chain
Blog June 26, 2026
Navigating global risk in the pharmaceutical supply chain
Biopharma CMC Commercialization
From complexity to clarity: Why patient-centered communication matters From complexity to clarity: Why patient-centered communication matters
Blog June 24, 2026
From complexity to clarity: Why patient-centered communication matters
Biopharma Biotech Commercialization
The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Biopharma Business Development Clinical trials
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
Biopharma Biotech Clinical trials
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Biopharma Biotech Clinical trials
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Biopharma Biotech Clinical trials
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Biopharma Biotech Clinical trials

Commercialization

온디맨드 웨비나 사이트런칭 온디맨드 웨비나 사이트런칭
Blog March 15, 2022
온디맨드 웨비나 사이트런칭
Tracking the mid-year momentum of the 2026 Drugs to Watch Tracking the mid-year momentum of the 2026 Drugs to Watch
Blog July 8, 2026
Tracking the mid-year momentum of the 2026 Drugs to Watch
Navigating global risk in the pharmaceutical supply chain Navigating global risk in the pharmaceutical supply chain
Blog June 26, 2026
Navigating global risk in the pharmaceutical supply chain
From complexity to clarity: Why patient-centered communication matters From complexity to clarity: Why patient-centered communication matters
Blog June 24, 2026
From complexity to clarity: Why patient-centered communication matters
The competitive signals hiding in plain sight for biopharma The competitive signals hiding in plain sight for biopharma
Blog May 8, 2026
The competitive signals hiding in plain sight for biopharma
Why ease of administration in new drugs sometimes draws a yawn from payers Why ease of administration in new drugs sometimes draws a yawn from payers
Blog February 26, 2026
Why ease of administration in new drugs sometimes draws a yawn from payers
The path forward: What comes after a CRL? The path forward: What comes after a CRL?
Blog February 24, 2026
The path forward: What comes after a CRL?
Tolebrutinib: when safety concerns override efficacy signals Tolebrutinib: when safety concerns override efficacy signals
Blog February 24, 2026
Tolebrutinib: when safety concerns override efficacy signals
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Blog February 24, 2026
Navigating Complete Response Letters: how Clarivate solutions can help pharmas chart their path to approval
Key market access considerations for long-acting and alternative delivery therapies Key market access considerations for long-acting and alternative delivery therapies
Blog February 20, 2026
Key market access considerations for long-acting and alternative delivery therapies
The market access “sweet spots” where payers reimburse more convenient therapies The market access “sweet spots” where payers reimburse more convenient therapies
Blog February 19, 2026
The market access “sweet spots” where payers reimburse more convenient therapies